We hold alliances with academic institutions and other bio-pharmaceutical companies at the core of our growth strategy, helping to seize the most promising opportunities while mitigating risk for investors. In addition, we seek business development partnerships on our robust pipeline.
iCo Therapeutics is a reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. We have licensed Bertilimumab (iCo-008) for systemic uses. The drug was originally developed by Cambridge Antibody Technology (now MedImmune, the biologics division of AstraZeneca). iCo Therapautics licensed in the drug from CAT before granting Immune an option to in-license bertilimumab for non-ophthalmic indications. iCo retains the rights for the ophthalmic indications. Learn more at icotherapeutics.com
Lonza is one of the world leaders in contract manufacturing of monoclonal antibodies and recombinant proteins using mammalian cell culture. We licensed the GS system from Lonza for the manufacturing process of Bertilimumab. Learn more at lonza.com
Yissum is the technology transfer company of the Hebrew University of Jerusalem. The University's range of intellectual property includes inventions and know-how in many fields, including nanotechnology, medicine and pharmaceuticals, agriculture and nutrition, water and environmental technologies, computer science, homeland security, and more. Learn more at yissum.co.li